Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE fingolimod coping evaluation study
2011-001280-49Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Primary endpoint: Change in HADS anxiety subscore. Started Apr 2011; status: completed.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2011-001280-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001280-49.